EP1553091A4 — Heteroaromatic pentacyclic compound and medicinal use thereof
Assigned to Japan Tobacco Inc · Expires 2007-01-17 · 19y expired
What this patent protects
A heteroaromatic pentacyclic compound of the general formula: [I] [wherein V is CH or N; W is S or O; each of R1 and R2 is H, etc.; X is -N(R4)-, -O-, -S-, -SO2-N(R5)-, -CO-N(R7)-, etc.; L is formula [II]; (Each of R20, R21, R22 and R25 is H, etc.; and E is an aryl or an aromatic…
USPTO Abstract
A heteroaromatic pentacyclic compound of the general formula: [I] [wherein V is CH or N; W is S or O; each of R1 and R2 is H, etc.; X is -N(R4)-, -O-, -S-, -SO2-N(R5)-, -CO-N(R7)-, etc.; L is formula [II]; (Each of R20, R21, R22 and R25 is H, etc.; and E is an aryl or an aromatic heterocycle); R is -COOH, etc.; B is an aryl, etc.; R3 is H, etc.; Y is -C(R13)(R14)-N(R12)-, -C(R13)(R14)-O-, -N(R11)-, -O-, etc.; A is an alkylene; Z is an aryl, etc.; etc.]. This compound or its prodrug or a pharmaceutically acceptable salt thereof has a protein tyrosine phosphatase 1B inhibiting activity and is useful as a curative medicine for diabetes mellitus, diabetes mellitus complications, hyperlipemia or obesity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.